Chardan Capital Has Negative Outlook of FBRX FY2025 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Equities research analysts at Chardan Capital cut their FY2025 earnings per share estimates for Forte Biosciences in a research report issued to clients and investors on Wednesday, April 2nd. Chardan Capital analyst D. Gataulin now expects that the company will post earnings of ($4.25) per share for the year, down from their prior forecast of ($4.03). Chardan Capital currently has a “Buy” rating and a $61.00 price target on the stock. The consensus estimate for Forte Biosciences’ current full-year earnings is ($12.12) per share. Chardan Capital also issued estimates for Forte Biosciences’ FY2026 earnings at ($2.04) EPS.

Separately, TD Cowen initiated coverage on shares of Forte Biosciences in a report on Tuesday, January 21st. They issued a “buy” rating for the company.

Forte Biosciences Trading Down 10.6 %

FBRX opened at $5.88 on Monday. Forte Biosciences has a 1-year low of $4.11 and a 1-year high of $28.68. The stock has a market capitalization of $38.70 million, a PE ratio of -0.36 and a beta of 2.52. The firm has a 50-day moving average price of $9.54 and a two-hundred day moving average price of $11.67.

Institutional Trading of Forte Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP acquired a new stake in shares of Forte Biosciences during the 4th quarter worth approximately $4,639,000. Tybourne Capital Management HK Ltd. grew its holdings in Forte Biosciences by 327.6% during the 4th quarter. Tybourne Capital Management HK Ltd. now owns 619,981 shares of the company’s stock worth $14,080,000 after acquiring an additional 475,000 shares during the period. Orbimed Advisors LLC acquired a new stake in Forte Biosciences during the 4th quarter worth $13,626,000. Fred Alger Management LLC raised its position in shares of Forte Biosciences by 1,271.2% during the 4th quarter. Fred Alger Management LLC now owns 1,133,944 shares of the company’s stock valued at $25,752,000 after acquiring an additional 1,051,246 shares during the last quarter. Finally, BVF Inc. IL lifted its stake in shares of Forte Biosciences by 398.2% in the 4th quarter. BVF Inc. IL now owns 594,282 shares of the company’s stock valued at $13,496,000 after purchasing an additional 475,000 shares during the period. 77.63% of the stock is owned by institutional investors.

About Forte Biosciences

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.